Vedanta Biosciences to Present at Upcoming Investor Conferences
Vedanta Biosciences will lay off 12 workers from its CMC team, and a “similar number” of staffers in other positions, as the company is “coming off a peak of manufacturing campaigns that supplied several mid and late-stage clinical studies,” CEO Bernat Olle wrote Friday on LinkedIn.
Vedanta Bio to Host Investor Meetings at the Leerink Partners 2024 Conference
Vedanta’s Key Microbiome Patents Fully Upheld in European Opposition Proceedings
Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023
Vedanta Biosciences to Participate at Upcoming Investor Conferences
Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference